|Application ||WB, IHC|
|Calculated MW||17935 Da|
|Other Names||Thy-1 membrane glycoprotein, CDw90, Thy-1 antigen, CD90, THY1|
|Target/Specificity||A synthetic peptide corresponding to residues near the N-terminal of human CD90 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CD90 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||May play a role in cell-cell or cell-ligand interactions during synaptogenesis and other events in the brain.|
|Cellular Location||Cell membrane; Lipid-anchor, GPI-anchor|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CD90 (Cluster of Differentiation 90, Thy-1) is a heavily N-glycosylated GPI linked cell surface protein member of the immunoglobulin (Ig) superfamily. As a smallest member of family, CD90 may play a role in cell-to-cell and cell-to-lignand interactions during synaptogensis and other neuron related activities (e.g. neurite outgrowth, nerve regeneration) (1). In developing nervous tissue, CD90 is involved in axon growth regulation by halting axon growth in mature axon via its interaction with intergin-beta-3 on mature astrocytes. Additionally, CD90 has been linked to apoptosis, adhesion, migration, cancer (including cancer stem cells), and fibrosis (2). As a major marker for hematopoietic stem cells (HSCs), CD90 mediates differentiation of HSCs. In stem cancer cell research, CD90+ cells in the hepatocellular carcinoma (HCC) have been shown to display tumorgenic capacity (3).
1. The UniProt Consortium, The Universal Protein Resource (UniProt). Nucleic Acids Res. 36:D190-D195 (2008) 2. TA Rege, JS Hagood., The FASEB Journal 20:1045-1054, 2006 3. ZF Yang et al., Cancer Cell 3(2):153-66, 2008.
If you have any additional inquiries please email technical services at email@example.com.